Zusammenfassung
Die vorliegende Krankheitskostenstudie fokussiert auf die Kosten, die aktuell bei der Behandlung von Patienten mit COPD (chronische obstruktive Lungenkrankheit) entstehen. In einer Vorstudie wurden die Daten von 814 zufällig ausgewählten Patienten retrospektiv erhoben, um die Verteilung der COPD-Schweregrade und Häufigkeiten von Exazerbationen zu ermitteln. In der Hauptstudie wurde der Ressourcenverbrauch von 321 zufällig aus der Vorstudie ausgewählten Patienten erhoben und die Kosten für jeden Schweregrad berechnet. Die Gesamtkosten der COPD wurden durch die Gewichtung der Kosten pro Schweregrad ermittelt. Aus volkswirtschaftlicher Sicht belaufen sich die durchschnittlichen jährlichen Kosten im Zusammenhang mit COPD auf € 3027 pro Patient. Krankenhausaufenthalte (26 %), Medikamente (23 %) und Frührente (17 %) verursachten den Hauptteil dieser Kosten. Aus Sicht der gesetzlichen Krankenversicherung lagen die Kosten pro Patient und Jahr bei € 1944.
Abstract
The present cost-of-illness study is focused on the costs of COPD in Germany. In a pre-study, data on 814 randomly selected patients were collected to achieve reliable figures for the distribution of COPD severity grades and the frequencies of exacerbations. The main study was performed on 321 randomly selected patients from the pre-study. Data on resource use were collected in a face-to-face interview with the respective physicians using the patient records as a basis. Costs associated with resource consumption were weighted with the frequencies of COPD severity grades as assessed in the pre-study to determine the costs of COPD. Annual COPD-related costs per patient were € 3,027 from the societal perspective. Main cost components were hospitalisations (26 %), medication (23 %) and early retirement (17 %). Annual COPD-related costs from the perspective of the German health insurance system (GKV) were € 1,944 per patient.
Literatur
1 GOLD-Workshop .Global initiative for chronic obstructive lung disease. http://www.goldcopd.com/workshop 2003
2
Murray C J, Lopez A D.
Mortality by cause for eight regions of the world: Global Burden of Disease Study.
Lancet.
1997;
349 (9064)
1498-1504
3 Nowak D, Konietzko N. (Hrsg) .Bronchitis. München: Urban und Schwarzenberg Verlag 1995: 233-253
4
Rychlik R, Pfeil T, Daniel D. et al .
Socioconomic relevance of acute exacerbations of chronic bronchitis in the Federal Republic of Germany. A prospective cost of illness study.
Dtsch Med Wochenschr.
2001;
126 (13)
353-359
5
Sullivan S D, Ramsey S D, Lee T A.
The economic burden of COPD.
Chest.
2000;
117 (2) Supplement
5S-9S
6
ATS statement .
Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
1995;
152
77-120
7 Sachverständigenrat .Bedarfsgerechtigkeit und Wirtschaftlichkeit. Band III, Über-, Unter- und Fehlversorgung. (http://www.svr-gesundheit.de) 2000/2001
8
Rodriguez-Roisin R.
Toward a consensus definition for COPD exacerbations.
Chest.
2000;
117/5
398-401
9
Stang P, Lydick E, Silberman C. et al .
The prevalence of COPD: using smoking rates to estimate disease frequency in the general population.
Chest.
2000;
117 (5 Suppl 2)
354S-359S
10
Bakke P S, Baste V, Hanoa R. et al .
Prevalence of obstructive lung disease in a general population: relation to occupation title and exposure to some airborne agents.
Thorax.
1991;
46
863-870
11
Viegi G, Scognamiglio A, Baldacci S. et al .
Epidemiology of chronic obstructive pulmonary disease (COPD).
Respiration.
2001;
68
4-19
12
Lawrence A D, Keaney N P.
Classification of COPD patients using airflow limitation significantly underestimates the clinical impact of the disease. Poster at the ATS.
Abstract published in Am J Respir Crit Care Med.
2002;
165
A442
13
Hilleman D E, Dewan N, Malesker M. et al .
Pharmacoeconomic evaluation of COPD.
Chest.
2000;
118
1278-1285
14
Vincken W, Noord J A van, Greefhorst A PM. et al .
Improved health outcomes in patientes with COPD during 1yr's treatment with tiotropium.
Eur Respir J.
2002;
19
209-216
15
Casaburi R, Mahler D A, Jones P W. et al .
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease.
Eur Respir J.
2002;
19
217-224
16
Calverley P, Pauwels R, Vestbo J. et al .
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
Lancet.
2003;
361
449-456
17
Szafranski W, Cukier A, Ramirez A. et al .
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.
Eur Respir J.
2003;
21
74-81
18 MediPlus Pro IMS .Version 4.2.17. Stand 09/02
19
Worth H, Buhl R, Cegla U. et al .
Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD).
Pneumologie.
2002;
56
704-738
20
Kornmann O, Beeh K M, Beier J. et al .
Global Initiative for Obstructive Lung Disease. Newly diagnosed chronic obstructive pulmonary disease. Clinical features and distribution of the novel stages of the Global Initiative for Obstructive Lung Disease.
Respiration.
2003;
70 (1)
67-75
21
Dietrich E S, Schoop S, Bartmann P. et al .
Arzneimitteltherapie in Deutschland - Bedarf und Realität.
KBV-Kontext Nr. 21.
2003;
59
22 Behr J, Nowak D. Tobacco smoke and respiratory disease. In: d'Amato G, Holgate ST (Eds). The impact of air pollution on respiratory health. European Respiratory Monograph 2002 21 (7): 161-179
23
Brusasco V, Hodder R, Miravitlles M. et al .
Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.
Thorax.
2003;
58
399-404
24
Oostenbrink J B, Rutten-van Molken M P, Al M J. et al .
One-year cost-effctiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease.
Eur Respir J.
2004;
23
241-249
25
Burge P S, Calverley P M, Jones P W. et al .
Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.
BMJ.
2000;
320
1297-1349
26
Highland K B, Strange C, Heffner J E.
Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-anaylsis.
Ann Intern Med.
2003;
138
969-973
27
Spencer S, Calverley P M, Burge P S. et al .
Impact of preventing exacerbations on deterioration of health status in COPD.
Eur Respir J.
2004;
23
698-702
28
Behnke M, Jörres R A, Kirsten D. et al .
Clinical benefits of a combined hospital and home-based exercise programme over 18 months in patients with severe COPD.
Monaldi Arch Chest Dis.
2003;
59
44-51
Prof. Dr. med. Dennis Nowak
Klinikum der Ludwig-Maximilians-Universität · Institut und Poliklinik für Arbeits- und Umweltmedizin
Ziemssenstr. 1
80336 München ·
Email: Dennis.Nowak@med.uni-muenchen.de